Jason Jardine, Makoto Tsunozaki Ph.D. On August 14, 2024, the U.S. Food and Drug Administration (FDA) approved a colony stimulating factor-1 receptor (CSF-1R)-blocking antibody, NIKTIMVO ...
The yield of peripheral blood stem cells (PBSC) in hematological or solid tumour patients treated with high dose chemotherapy and hemopoietic growth factors No significant financial relationships to ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
Purpose. The efficacy and safety of granulocyte colony-stimulating factor (G-CSF) in critically ill patients with severe sepsis or septic shock were evaluated. Summary. The medical literature was ...
The effects of sargramostim and filgrastim on hematopoietic cells are described. Filgrastim is a lineage-specific colonystimulating factor (CSF), mainly affecting neutrophils. In addition to enhancing ...
Infections with cytomegalovirus (CMV) are extremely common and often pose no major threat to the vast majority of people. They can however be deadly for people whose immune system is weakened, for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results